Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003116759 | SCV003792971 | likely pathogenic | Mosaic variegated aneuploidy syndrome 2 | 2022-01-19 | criteria provided, single submitter | clinical testing | In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. This variant has not been reported in the literature in individuals affected with CEP57-related conditions. This variant results in the deletion of exons 5-9 and part of exon 10 (c.505-1332_1235del) of the CEP57 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in CEP57 are known to be pathogenic (PMID: 21552266, 24259107). |